To: Board of Supervisors
From: Dr. Grant Colfax, Health Services Director
Report Title: Contract Amendment #76-752-3 with Roche Diagnostics Corporation
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Health Services Director, or designee, to execute on behalf of the County Contract Amendment #76-752-3 with Roche Diagnostics Corporation, a corporation, to amend Contract #76-752 (as amended by Contract Amendments #76-752-1 and #76-752-2), effective October 1, 2025, for additional products, reagents and supplies for the Cobas laboratory analyzer used for patient specimen testing at Contra Costa Regional Medical Center (CCRMC) and to correct the original termination date from December 31, 2032 to February 9, 2030, with no change in the payment limit of $2,577,330.
FISCAL IMPACT:
Approval of this Contract Amendment will not impact the original payment limit of $2,577,300 funded 100% by Hospital Enterprise Fund I revenues. (No rate increase)
BACKGROUND:
This Contract meets the needs of CCRMC and its health centers, allowing the Roche Cobas 5800 System, aiding in the automation, integration, consolidation, and standardization of high-volume and molecular testing such as COVID-19 and influenza and allows in-house testing. The Roche Cobas 5800 System includes ancillary test equipment, reagents, and supplies for CCRMC clinical laboratories and pathology to process, test, and analyze patient specimens. CCRMC has been using Roche products since 2010.
On December 21, 2021, the Board of Supervisors approved Contract #76-752 with Roche Diagnostics Corporation, in the amount not to exceed $1,530,425, for the purchase of the Roche Cobas 6800 fully automated patient specimen testing system for the period August 11, 2021, through August 10, 2026.
On February 27, 2024, the Board of Supervisors approved Contract Amendment #76-752-1 with Roche Diagnostics Corporation, effective February 27, 2024, to increase the payment limit by $1,046,875 to a new total of $2,577,300 and extend the term through December 31, 2032, and allow CCRMC to trade in the Cobas 6800 and upgrade its current testing platform to the Cobas 5800 analyzer, which includes specifications required by the Centers for Medicare & Medicaid Services to meet Clinical Laboratory Improvement Amendments and Federal Drug Administration accreditation requirements.
On February 25, 2025, the Board of Supervisors approved Contract Amendment #76-752-2, with Roche Diagnostics Corporation, effective upon execution of this agreement, for additional test kits, reagents and supplies for the Cobra laboratory analyzer used for patient specimen testing at CCRMC, with no change in the payment limit of $2,577,300 or term.
The extension date was to be 60 months from the commencement date for the Roche Cobas 5800 making the correct contract termination date February 9, 2030.
Approval of Contract Amendment #76-752-3 will allow the Contractor to provide additional products, reagents and supplies needed for patient testing and correct the termination date to February 9, 2030.
CONSEQUENCE OF NEGATIVE ACTION:
If this Contract Amendment is not approved, Contra Costa Health will not have the necessary products, reagents and supplies needed for specimen testing at CCRMC needed for patient care.